After a ten-year long criminal investigation, Johnson & Johnson has entered a guilty plea and will pay $2.2 billion in damages. The U.S. Department of Justice charged the company with promoting the drugs Risperdal and Invega for off-label uses (uses that were not approved by the FDA). These drugs were approved solely for the treatment of schizophrenia, but Johnson & Johnson was promoting them for non-schizophrenic patients—including children, ...
continue reading...Johnson & Johnson Guilty Plea Helps Risperdal Lawsuits
Posted November 19, 2013 in Health | Product Liability | Product News and Recalls | Verdicts & Settlements